Skip to main content
Evidence Snapshot

Cyclin-dependent kinase 16

CHEMBL4597 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:06Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4597
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-dependent kinase 16 as ChEMBL target CHEMBL4597, mapped to UniProt Q00536. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cyclin-dependent kinase 16
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4597
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q00536
Cyclin-dependent kinase 16
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Cyclin-dependent kinase 16 matters

As of 2026-09-14

Cyclin-dependent kinase 16 is reviewed as Cyclin-dependent kinase 16 (UniProt Q00536); the current evidence base includes 16 approved drugs, 704 compounds, and 174 assays, with lead potency reaching pChEMBL 9.3.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 704 compounds, and 174 assays for this target. The dominant activity type is KD. CHEMBL384304 is the current potency anchor at pChEMBL 9.3.

Use CHEMBL384304 as the tractability anchor when discussing potency (pChEMBL 9.3).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 9.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Cyclin-dependent kinase 16 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q00536, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

704
Total Compounds
174
Total Assays
16
Approved Drugs
IC50: 13.0, EC50: 1.0, KD: 388.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL384304
 9.3 Kd Clinical
No preferred name
CHEMBL445813
 9.0 Kd Clinical
No preferred name
CHEMBL3545083
 8.5 Kd —
No preferred name
CHEMBL296468
 8.2 Kd —
No preferred name
CHEMBL1082152
 7.9 Kd —

Approved Drugs

Structure Compound First Approval
ABEMACICLIB
CHEMBL3301610
 2017
RUCAPARIB
CHEMBL1173055
 2016
NINTEDANIB
CHEMBL502835
 2014
DABRAFENIB
CHEMBL2028663
 2013
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:06Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4597